Nasdaq-Listed Prenetics Launches Genomics-Based Partnership with Humanity Protocol and Unveils Crypto Strategic Reserve

Prenetics Global Limited (NASDAQ: PRE), a leading genomics and consumer healthcare company, is partnering with Humanity Protocol. This collaboration leverages Prenetics’ advanced genetic testing capabilities to underpin decentralized identity verification, while simultaneously unveiling a Crypto Strategic Reserve aimed at fueling innovation at the intersection of blockchain, healthcare, and decentralized science (DeSci).

As part of this dual initiative, Prenetics is committing initial investments of $1 million in $H tokens, $250,000 in Bitcoin (BTC), and $250,000 in Solana (SOL). These allocations, which will be revisited on a quarterly basis to assess further investment opportunities, underscore the company’s strategic intent to integrate digital assets into its corporate balance sheet. Prenetics’ cash and short-term assets balance stood at $84.87 million as of December 31, 2024, reflecting its robust financial position to support these initiatives.

With the partnership, Prenetics will join Humanity Protocol as an Identity Validator, bringing its flagship CircleDNA service into the protocol's infrastructure. This integration enables the issuance of blockchain-based Proof of Personhood credentials, leveraging DNA testing to deliver highly secure and sybil-resistant identity verification. With advanced zero-knowledge proof technology, these credentials ensure robust privacy protection while supporting decentralized applications across finance, healthcare, and governance.

Danny Yeung, CEO and Co-Founder of Prenetics, stated: “Our partnership with Humanity Protocol exemplifies our commitment to merging the precision of genomics with the transformative potential of blockchain technology. Through our CircleDNA service, we will provide secure, privacy-focused identity solutions that not only benefit decentralized applications across finance, healthcare, and governance but also pave the way for further integration of digital assets into our strategic framework.”

Yat Siu, Board Director of the Humanity Foundation and Executive Chairman of Animoca Brands, added: “Prenetics’ entry into the decentralized identity arena as an Identity Validator marks a significant milestone. Their deep expertise in genomics, now combined with an active role in the Web3 ecosystem, is exactly the kind of forward-thinking collaboration that will drive decentralized identity and secure digital interactions into the future.”

Unveiling the Crypto Strategic Reserve Prenetics’ newly established Crypto Strategic Reserve is a testament to the company’s belief in blockchain’s capacity to drive cross-industry innovation.

“Our Crypto Strategic Reserve demonstrates Prenetics’ confidence in the transformative potential of blockchain and digital assets,” said Danny Yeung, CEO and Co-Founder of Prenetics. “This initiative not only diversifies our portfolio but also reinforces our commitment to leveraging cutting-edge technologies to drive cross-industry innovation in healthcare and beyond.”

This strategic allocation reflects Prenetics’ commitment to diversifying its investment portfolio while reinforcing its leadership in technological innovation.

About Prenetics 

Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a new health and wellness brand, and Europa, one of the largest sports distribution companies in the USA. Our clinical division is led by Insighta, our $200 million venture focused on multi-cancer early detection technologies. Each of Prenetics’ units synergistically enhances our global impact on health, embodying our commitment to ‘enhancing life through science’. To learn more about Prenetics, please visit prenetics.com.